Verastem stocktwits
Verastem Oncology Condensed Consolidated Balance Sheets (in thousands) (unaudited) December 31, 2023 December 31, 2022 Cash, cash equivalents, & investments $ 137,129 $ 87,894 Accounts receivable, net — 31 Prepaid expenses and other current assets 6,553 4,945 Property and equipment, net 37 92 Right-of-use asset, net 1,171 1,789 Restricted …Also, Verastem will be presenting preclinical data on Avutometinib synergies with several target-specific agents for RAS-driven cancers that advance our collective understanding of how to tackle these pervasive and virulent mutations. The subject of more than 30 years of research, RAS is the most frequently mutated oncogene in human cancers.Verastem Oncology is currently conducting clinical trials with its RAF/MEK clamp avutometinib in RAS/MAPK driven tumors as part of its (Raf And Mek Program). RAMP 301 (NCT06072781) is a Phase 3 ...
Did you know?
An outbreak at local lockups could overwhelm area hospitals. Details emerging about conditions at a Massachusetts jail—one of the 637 facilities nationwide that US Immigration and ...Track Apellis Pharmaceuticals Inc (APLS) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsVerastem Oncology is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index. Wikipedia. Headquarters: Massachusetts. Founded: 2010. CEO: Brian Stuglik (Jul 2019–)This means patients quickly run out of therapeutic options. At Verastem Oncology, we’re committed to ensuring options exist. For more information about the work we’re doing at Verastem Oncology, please access our Resources section or contact Julissa Viana via email at [email protected]. Press Releases. Media Kit.The Verastem stock price fell by -66.17% on the last day (Friday, 24th May 2024) from $12.18 to $4.12. During the last trading day the stock fluctuated 30.60% from a day low at $4.02 to a day high of $5.25. The price has been going up and down for this period, and there has been a -65.23% loss for the last 2 weeks.BOSTON, January 29, 2024--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today outlined key 2024 strategic priorities ...What this means: Verastem Inc (VSTM) gets a very positive evaluation from InvestorsObserver's ranking system. An Overall Rank of 86 means that our comprehensive methodology rates Verastem Inc above 86% of stocks. Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a …Verastem's (VSTM) avutometinib/Lumakras combination therapy gets the FDA's Fast Track designation to treat KRAS G12C-mutant metastatic NSCLC patients. The stock gains 8% in response.Verastem Oncology is currently conducting clinical trials with its RAF/MEK clamp avutometinib in RAS/MAPK driven tumors as part of its (Raf And Mek Program). RAMP 301 (NCT06072781) is a Phase 3 ...The S&P 500 tech stock index has climbed 11% year to date. Get the latest Verastem Inc. (VSTM) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.Find the latest Verastem, Inc. (VSTM) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Verastem was founded on the belief that most currently marketed anti-cancer drugs have little efficacy against cancer stem cells (CSCs), a progenitor subgroup of cells that some scientists believe ...In the previous week, Verastem had 5 more articles in the media than Akebia Therapeutics. MarketBeat recorded 12 mentions for Verastem and 7 mentions for Akebia Therapeutics. Verastem's average media sentiment score of 0.64 beat Akebia Therapeutics' score of 0.46 indicating that Verastem is being referred to more favorably …View the latest Verastem Inc. (VSTM) stock price, news, historical charts, analyst ratings and financial information from WSJ.Verastem Oncology is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index. Wikipedia. Headquarters: Massachusetts. Founded: 2010. CEO: Brian Stuglik (Jul 2019-)BOSTON - Verastem Oncology (Nasdaq: VSTM) (the 'Company'), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today results of the efficacy and safety of avutometinib and defactinib in recurrent low-grade serous ovarian cancer (LGSOC) following prior systemic therapy.. The results of this planned subgroup analysis of Part A of the Phase 2 RAMP ...BOSTON, January 29, 2024--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today outlined key 2024 strategic priorities ...Verastem Oncology is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index. Wikipedia. Headquarters: Massachusetts. Founded: 2010. CEO: Brian Stuglik (Jul 2019–)Verastem is currently enrolling KRAS G12C inhibitor-resistant and naïve KRAS G12C-mutant NSCLC patients in the expansion phase of the RAMP 203 study. Updated results from the study are expected ...Claim your Free Employer Profile. www.verastem.com. Needham, MA. 51 to 200 Employees. 1 Location. Type: Company - Public (VSTM) Founded in 2010. Revenue: $5 to $25 million (USD) Biotech & Pharmaceuticals.Verastem Oncology (Nasdaq: VSTM) is a late-The consensus estimate for Verastem's current This press release includes forward-looking statements about Verastem Oncology's strategy, future plans and prospects, including statements related to cash runway, the potential clinical value of various of its clinical trials, the timing of commencing and completing trials, including topline data reports, and potential for additional ... Track Atlassian Corporation Plc (TEAM) Stock P Jeffersonville, Indiana is one of the best places to live in the U.S. in 2022 because of its low cost of living and ample things to do. Becoming a homeowner is closer than you thin... Verastem Trading Up 2.5 %. Shares of NASDAQ:
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), ANI Pharmaceuticals (ANIP) and Argenx Se (ARGX) May 13, 2024TipRanks. RBC Capital Sticks to Their Buy Rating for Verastem (VSTM ...BOSTON--(BUSINESS WIRE)--Sep. 22, 2021-- Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Louis J. Denis, M.D., as Chief Medical Officer. Dr. Denis brings more than 25 years of clinical development and oncology expertise to Verastem.. This press release features multimedia.Welcome to Stocktwits! Share messages with cash tags e.g. $GLD or $AAPL and join the community. Make sure you also download our mobile apps for iOS and Android.Mar 14, 2024 · BOSTON, March 14, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three ...Track Virios Therapeutics Inc (VIRI) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors
Track Arm Holdings Plc. (ARM) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsVSTM Stock 12 Months Forecast. $31.67. (187.91% Upside) Based on 3 Wall Street analysts offering 12 month price targets for Verastem in the last 3 months. The average price target is $31.67 with a high forecast of $36.00 and a low forecast of $27.00. The average price target represents a 187.91% change from the last price of $11.00.…
Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Published: May 23, 2024 at 6:47 p.m. ET. By Ben Glickman. . Possible cause: Find the latest Verastem, Inc. (VSTM) stock discussion in Yahoo Finance's forum. Sha.
(RTTNews) - Verastem (VSTM) said that the U.S. Food and Drug Administration has granted Fast Track Designation to Verastem Oncology's investigational RAF/MEK clamp, avutometinib, in combination ...Track Candel Therapeutics Inc (CADL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsTrack Novavax Inc (NVAX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors
Verastem Oncology is currently evaluating the efficacy and safety of VS-6766 alone and in combination with defactinib in the registration-directed Phase 2 RAMP 201 (Raf And Mek Program) (ENGOTov60 ...Track Vera Therapeutics Inc - Ordinary Shares - Class A (VERA) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors
Track Meta Platforms Inc (META) Stock Price, BOSTON, December 18, 2023--Verastem Oncology (Nasdaq: VSTM) (the "Company"), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced a potential ... Track Microsoft Corp (MSFT) Stock Price, QuoVerastem, Inc. is a biopharmaceutical company, whic Insiders have sold a total of 16,432 Verastem shares in the last 24 months for a total of $168,350.95 sold. This page (NASDAQ:VSTM) was last updated on 5/25/2024 by MarketBeat.com Staff.Novel therapies and combinations are urgently needed to deliver on the promise of better outcomes for patients. Find out more about our clinical trials. At Verastem Oncology, we recognize and prioritize the importance of partnership with the research and patient advocacy communities to create and support approaches to better care. Mizuho Securities analyst Mara Goldstein maintained a Hold rat For many patients with difficult-to-treat cancers, the options have been few. Verastem Oncology aims to change that by pursuing RAS pathway-targeted treatment combinations with avutometinib (VS-6766). Find out more about our clinical trials here. FIND A TRIAL. Verastem-Sponsored Trials Investigator-Sponsored Trials.Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), ANI Pharmaceuticals (ANIP) and Argenx Se (ARGX) May 13, 2024TipRanks. RBC Capital Sticks to Their Buy Rating for Verastem (VSTM ... Verastem Oncology (NASDAQ:VSTM) Thursday saidBOSTON--(BUSINESS WIRE)--Jun. 16, 2023-- VVerastem Oncology. Reconciliation of GAAP to Non-GA View Verastem, Inc VSTM investment & stock information. Get the latest Verastem, Inc VSTM detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer. BOSTON-- (BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today that it has ... Verastem (VSTM) Stock Price, News & Analysis. → WARNING about Insiders have sold a total of 16,432 Verastem shares in the last 24 months for a total of $168,350.95 sold. This page (NASDAQ:VSTM) was last updated on 5/25/2024 by MarketBeat.com Staff. Verastem, Inc. Common Stock (VSTM) Stock Quotes - NasdaqRBC Capital Markets, LLC. Gregory Renza. Truist. Srikripa D Free VSTM Stock Alerts. $11.50. -0.63 (-5.19%) (As of 05/17/2024 08:54 PM ET) Compare. Share. Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Options Chain Ownership SEC Filings Short Interest Social Media. Media Mentions Over Time. 10.A few Evernote apps will no longer be updated or available for download in the new year. These include screenshot and annotating tool Skitch and Clearly, which makes web pages more...